Journal of Clinical Oncology
Articles in this Issue
Bacillus Calmette-Guérin (BCG) treatment patterns and real-world outcomes in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): A systematic literature review (SLR).
730 Background: Transurethral resection followed by induction and maintenance intravesical BCG is currently standard of care for patients with HR NMIBC. H...
Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry.
736 Background: The treatment of advanced urothelial carcinoma (UC) has dramatically changed with the introduction of antibody-drug conjugates and immunot...
Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with chromophobe histology.
488 Background: Chromophobe (chRCC) renal cell carcinoma are rare cancers and obtain a worse prognosis. We evaluated real-world treatment outcomes of 1...
Targeting more than tumors: The impact of enfortumab vedotin and pembrolizumab (EV/P) on skeletal muscle loss and sarcopenia in metastatic urothelial carcinoma (mUC).
689 Background: Sarcopenia and skeletal muscle loss are associated with poor prognosis and limited survival in metastatic cancer patients. This study aims...
Survival outcomes based on line of therapy and treatment trends with cabazitaxel in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
162 Background: Pts with mCRPC after progression on docetaxel and androgen receptor pathway inhibitors (ARPIs), have limit...
A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).
TPS293 Background: Advanced mCRPC and metastatic ccRCC are urologic malignancies with poor prognoses, and novel therapies that can improve long-term outco...
Real world effectiveness of systemic treatment in patients (pts) with advanced upper tract urothelial carcinoma (UTUC) with histological variants.
722 Background: Upper tract urothelial carcinoma is a rare and heterogeneous disease that accounts for up to 5% of all urothelial neoplasms. Variant histo...
Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract urothelial carcinoma: A study focusing on temporal heterogeneity.
839 Background: The promising performance of HER2 antibody–drug conjugates (ADC) in clinical trials suggested that HER2-targerted therapy, particularly AD...
AVENANCE real-world study of avelumab first-line (1L) maintenance treatment for advanced urothelial carcinoma (UC): Analyses in low tumor burden subgroups.
718 Background: The effectiveness and safety of avelumab 1L maintenance was confirmed in the large real-world AVENANCE study in France. In patients with a...
A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).
795 Background: To evaluate the safety and efficacy of RC48-ADC, a humanized anti-HER2 antibody conjugated with monomethyl auristatin E, and tislelizumab,...
Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter RECOMMEND study.
89 Background: Darolutamide has authorisation for treatment of metastatic hormone sensitive prostate cancer (MHSPC) in combination with docetaxel chemothe...
Androgen receptor activity in biopsy specimens at initial diagnosis of prostate cancer and correlation with outcomes and treatment response.
409 Background: Androgen receptor activity (AR-A) has been described after radical prostatectomy (RP) and metastatic castration-sensitive prostate cancer...
Global spatiotemporal trends in prostate cancer burden and its socioeconomic disparities: An observational study from 1990 to 2021.
325 Background: Prostate cancer is the second most common cancer in men globally, posing significant health challenges. Conflicting findings on its global...
Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC).
526 Background: Existing HRQOL measures may not fully capture the experiences of patients with localized and advanced RCC. This study aimed to develop a v...
Safety and efficacy of salvage lymph node dissection in prostate cancer patients with nodal recurrence after radical prostatectomy: A prospective single center phase I/II study.
149 Background: Optimal management of pelvic nodal recurrence of prostate cancer after RP detected by PSMA-PET is still unclear, although a significant ch...
Impact of liquid biopsies on early detection, monitoring, and prognostication in prostate cancer: A meta-analysis of emerging evidence.
32 Background: Prostate cancer remains a leading cause of cancer-related morbidity and mortality among men worldwide. Traditional diagnostic and monitorin...
A phase III single-arm study to evaluate the efficacy and safety of paclitaxel-hyaluronic acid conjugate administered intravesically to patients with BCG-unresponsive carcinoma in situ of the bladder with or without Ta-T1 papillary disease (Orion-BC study).
TPS885 Background: Non-muscle invasive bladder cancer (NMIBC) is the most common bladder cancer, with Carcinoma in situ (CIS) being a precursor to muscle-...
Comparing the effectiveness of IO-based combination regimens as first-line treatment for advanced clear-cell renal cell carcinoma (ccRCC).
498 Background: IO-based combination therapies - either in combination with tyrosine kinase inhibitors (TKI) or as double checkpoint inhibition - have rev...
Extreme bipolar androgen therapy: Alternating darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer (mCRPC; ExBAT trial/LACOG 0620).
178 Background: Sequencing androgen-receptor signaling inhibitors (ARSi) has limited activity in metastatic castration-resistant prostate cancer (mCRPC)....
EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.
1 Background: Platinum-based combination chemotherapy remains the Standard of Care (SoC) treatment for patients with local...
Efficacy and safety of ifosfamide and mesna in metastatic castration-resistant prostate cancer after taxane-based chemotherapy and novel hormonal therapy failure.
174 Background: Limited treatment options exist for patients with metastatic castration-resistant prostate cancer (mCRPC) after the failure of taxane-base...
Second primary malignancy in bladder cancer: A retrospective population-based analysis.
676 Background: Bladder cancer is responsible for about 4% of cancers in the United States. It is the fourth most common cancer in men. A second primary m...
Efficacy and safety of immune checkpoint inhibitors (ICI) for the treatment of metastatic penile squamous cell carcinoma (mPSCC).
4 Background: Metastatic penile squamous cell carcinoma (mPSCC) is a rare and aggressive malignancy with limited treatment options. Standard systemic ther...
Impact of baseline PSMA PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) starting first-line (1L) androgen receptor signaling inhibitor (ARSI) therapy.
46 Background: The prognostic significance of PSMA positron-emission tomography (PET) uptake on prostate cancer (PC) outcomes is not well established. Hig...
National cancer system characteristics and prostate cancer outcomes: A global analysis.
24 Background: The number of prostate cancer cases globally is projected to double from 2020 to 2040. However, significant global variation exists in pros...